JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN)

Int J Hematol. 2020 Sep;112(3):268-291. doi: 10.1007/s12185-020-02964-0. Epub 2020 Aug 11.

Authors

Kazuya Shimoda¹, Naoto Takahashi², Keita Kirito³, Noriyoshi Iriyama⁴, Tatsuya Kawaguchi⁵, Masahiro Kizaki⁶

Affiliations

¹ Department of Gastroenterology and Hematology, University of Miyazaki, Miyazaki, Japan. kshimoda@med.miyazaki-u.ac.jp.
² Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
³ Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.
⁴ Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
⁵ Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan.
⁶ Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

PMID: 32783166
DOI: 10.1007/s12185-020-02964-0

No abstract available

Publication types

Review

MeSH terms

Cytarabine / administration & dosage
Dasatinib / therapeutic use*
Drug Monitoring
Drug Therapy, Combination
Fusion Proteins, bcr-abl / genetics
Hematopoietic Stem Cell Transplantation*
Humans
Imatinib Mesylate / therapeutic use*
Interferon-alpha / administration & dosage
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / genetics
Myeloproliferative Disorders / pathology
Myeloproliferative Disorders / therapy*
Neoplasm Staging
Practice Guidelines as Topic*
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*

Substances

BCR-ABL1 fusion protein, human
Interferon-alpha
Protein Kinase Inhibitors
Pyrimidines
Cytarabine
Imatinib Mesylate
Fusion Proteins, bcr-abl
nilotinib
Dasatinib